According to a recent LinkedIn post from Parallel Fluidics, the company is promoting on-site demonstrations of its LNP Screening Array for local biopharma teams in the Boston area. The post indicates that Parallel Fluidics aims to integrate its microfluidic lipid nanoparticle formulation workflow directly onto customers’ existing liquid-handling systems.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that the company is targeting higher engagement with regional biotech and biopharma labs by lowering adoption barriers through hands-on demos and complimentary Starter Arrays for initial campaigns. For investors, this outreach may signal a go-to-market push focused on lab automation and RNA-delivery workflows, potentially expanding the customer base in a strategically important hub for drug development.